If final European approval is granted, it is likely to be finalized in the second quarter of 2006. The product combines the Allergan’s eye drops Lumigan that reduces the pressure in the eye with timolol, used to treat high blood pressure.
Ganfort is indicated for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
“Adherence to therapy is an integral factor in the successful treatment of glaucoma and ocular hypertension. Combination therapies often reduce the number of medications required and can aid patients with compliance,” said Dr Scott Whitcup, Allergan’s executive vice president, R&D.